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Primary Epstein-Barr virus (EBV) infection causes infectious mononucleosis and 
hemophagocytic lymphohistiocytosis (HLH) in children, where EBV infects B and CD8+ 
T cells, respectively. We measured pro-inflammatory and anti-inflammatory cytokines in 
both diseases. Significantly higher concentrations of various mediators, including 
interferon-γ, neopterin, interleukin (IL)-6, IL-10, IL-18 and heme oxygenase-1, were 
observed in EBV-HLH. Because of their similarity to the profile of familial HLH, this 
profile was likely a consequence of HLH, but not ectopic infection. TNF-α levels were 
elevated in both diseases. Elevation of those mediators may contribute to the disease 





Epstein-Barr virus (EBV) is a ubiquitous virus that infects the majority of the 
world’s population [1]. Primary infection of EBV is usually asymptomatic but may cause 
infectious mononucleosis (IM). EBV infects B cells in EBV-associated IM (EBV-IM) 
and persists in B cells for the lifetime of the seropositive normal host. However, primary 
EBV infection has also been linked with hemophagocytic lymphohistiocytosis (HLH), 
which is an aggressive lymphoproliferative disorder [2,3]. Several reports have 
demonstrated that EBV infection is characterized by an increase in CD8+ T cells in EBV-
HLH, although the mechanism underlying ectopic EBV infection remains unclear [4-7]. 
  The symptoms of EBV-IM and EBV-HLH are associated with T-cell activation 
and cytokine production [8]. In EBV-IM, proliferation of activated antigen-specific and 
nonspecific cytotoxic CD8+ T cells leads to release of interferon (IFN)-γ, interleukin (IL)-
2, and tumor necrosis factor (TNF)-α [9,10]. Studies of cytokines from HLH patients 
have also demonstrated elevated concentration of many pro-inflammatory cytokines, such 
as IFN-γ, TNF-α, and IL-6 [11-13]. However, because HLH is a heterogenous group of 
disorders, most reports have contained subgroups with different disease etiologies [11-13]. 
Moreover, the cellular targets and clonality of EBV have not been well characterized, 
even in reports describing EBV-HLH [11-13]. It is therefore unknown whether the 
differential cellular targets of EBV lead to different cytokine profiles. In this report, we 





We studied 22 patients with primary EBV infection: 11 with EBV-HLH and 11 
with EBV-IM (Table I). All patients were previously healthy. The data of 6 patients with 
EBV-HLH have been reported elsewhere [5]. The remaining patients with EBV-HLH 
also showed typical clinical features of HLH and exhibited high viral copy numbers. It 
was noted that CD8+ T cells were the major cellular targets of EBV in all EBV-HLH 
patients by in situ hybridization for EBV-encoded small RNA1 in the available samples 
[5]. The diagnosis of EBV-IM was clinically determined. All patients with EBV-IM 
exhibited self-limited disease. Primary EBV infection was serologically confirmed for all 
cases of EBV-HLH and EBV-IM. We also investigated 4 cases of familial HLH (FHL) 
due to perforin deficiency as a disease control. Samples were collected during the acute 
phase of the diseases. The study was approved by the Human Research Committee of 
Kanazawa University Graduate School of Medical Science, and informed consent was 
obtained according to the Declaration of Helsinki. 
 
Cytokine determination 
Serum or plasma concentrations of cytokines were determined using the following 
ELISA kits: neopterin (IBL, Hamburg, Germany); IFN-γ, IL-6, TNF-α, soluble TNF 
receptor type 1 (sTNF-RI) and type 2 (sTNF-RII), and soluble CD163 (sCD163) (R&D 
systems, Minneapolis, MN); IL-18 (MBL, Nagoya, Japan); IL-10 (eBioscience, San 
Diego, CA); and heme oxygenase-1 (HO-1; Enzo, Ann Arbor, MI) [14,15]. Analysis of 
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significant differences among groups was performed using the Mann-Whitney U test. 





Patients with EBV-HLH exhibited high levels of IFN-γ, neopterin, IL-6, IL-18, 
TNF-α, sTNF-RI and sTNF-RII (Figure 1), all of which were statistically significant. 
Patients with EBV-IM also showed high concentrations of pro-inflammatory cytokines, 
albeit at lower levels than those of EBV-HLH. Six of 11 patients with EBV-IM showed 
high TNF-α levels similar to those of EBV-HLH, which was consistent with a previous 
report [9]. IL-10 was markedly elevated in patients with EBV-HLH, whereas patients 
with EBV-IM exhibited only modestly elevated IL-10 levels. The levels of sCD163 were 
elevated in both EBV-HLH and EBV-IM. Patients with EBV-HLH exhibited higher 





In this report, we describe cytokine profiles from children affected with EBV-
HLH and EBV-IM. While both diseases are characterized by acute systemic 
inflammatory responses induced by primary EBV infection, the clinical courses are quite 
different. EBV-HLH is a potentially fatal disease that often requires immune-modulating 
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chemotherapy, whereas EBV-IM is a benign self-limited disease. This difference may be 
fundamentally due to the differential cellular targets of EBV infection; EBV ectopically 
infects CD8+ T cells in EBV-HLH, while B cells are the target in EBV-IM [4-6]. 
Alternatively, the patients may develop HLH based on the ability of the immune system 
to cope with this pathogen.  However, it remains unknown whether the differential 
cellular targets of EBV lead to different cytokine profiles in the peripheral blood. To 
address this issue, serum or plasma concentrations of various cytokines were determined. 
Hypersecretion of pro-inflammatory cytokines produced by activated T cells and 
macrophages accounts for the severe systemic manifestations in HLH [2,3]. In fact, our 
patients with EBV-HLH exhibited profound hypercytokinemia. The high concentration of 
neopterin might indicate pathological activation of macrophages and involvement in the 
disease development of EBV-HLH [16]. These cytokine profiles were similar to those 
found in FHL caused by perforin deficiency, which is the most common form of genetic 
HLH [2,3]. The cytokine profile of EBV-HLH is therefore likely a general consequence 
of HLH, rather than a result of clonal proliferation of EBV-infected CD8+ T cells. Some 
patients with EBV-IM exhibited marked immune responses to regulate EBV-infected B 
cells and shared typical findings of HLH, such as cytopenia and hemophagocytosis. 
Because such patients tended to exhibit higher levels of pro-inflammatory cytokines, it 
was difficult to clearly distinguish EBV-HLH from EBV-IM based solely upon the 
cytokine profiles. However, we have used flow cytometry to detect EBV-infected cells in 
EBV-HLH as clonally-expanded and highly-activated CD8+ T cells with CD5 
downregulation [5,6]. Since suppression of severe hyperinflammation and eradication of 
EBV-infected cells are crucial in treatment of EBV-HLH [17], the combined analysis of 
 7 
cytokine profiles and our flow cytometry approach may be useful in follow-up of patients 
with EBV-HLH. 
 To evaluate the anti-inflammatory responses in EBV-HLH and EBV-IM, we also 
analyzed circulating mediators, including IL-10, sCD163 and HO-1 (Figure 1). IL-10 
plays multiple roles in immunosuppression and contributes to maintaining the balance of 
the immune system in inflammation. Consistent with previous reports [11-13], IL-10 was 
markedly elevated in EBV-HLH patients. EBV-infected cells in EBV-HLH secrete viral 
IL-10, a product of the EBV replication gene BCRF1, which shares structural and 
functional similarity with human IL-10 [18]. However, patients with FHL exhibited 
levels of IL-10 that were comparable to EBV-HLH, suggesting that the high IL-10 levels 
in EBV-HLH were likely a consequence of HLH itself. Further studies using ELISA that 
can distinguish between human and viral IL-10 will be necessary. A soluble hemoglobin 
scavenger receptor (sCD163) is also shed from the monocyte-macrophage membrane 
upon inflammatory stimuli and reflects anti-inflammatory processes [15]. Interestingly, 
our results for sCD163 indicate alternative activation of macrophages, in addition to 
classical activation, in primary EBV infection. HO-1 is the rate-limiting enzyme in the 
heme breakdown pathway, and has potent anti-inflammatory, anti-apoptotic, and anti-
oxidative effects [19]. It has recently been reported that HO-1 is useful in the differential 
diagnosis of secondary HLH [20]. Indeed, our EBV-HLH patients exhibited higher levels 
of HO-1. Taken together, the profiles of anti-inflammatory mediators among EBV-HLH, 
EBV-IM, and FHL were largely similar to the profiles of pro-inflammatory cytokines. 
In summary, our studies demonstrate significantly higher concentrations of both 
pro-inflammatory cytokines and anti-inflammatory mediators in EBV-HLH compared 
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with EBV-IM. These profiles may contribute to the disease pathogenesis of EBV-HLH 
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Fig. 1.   Cytokine profiles in patients with EBV-HLH, EBV-IM, and FHL. 
Serum or plasma concentrations of interferon-γ, neopterin, interleukin (IL)-6, IL-18, 
tumor necrosis factor (TNF)-α, soluble TNF receptor type 1 (sTNF-RII) and type 2 
(sTNF-RII), IL-10, soluble CD163 (sCD163) and heme oxygenase-1 (HO-1). Horizontal 
bars indicate the median values. Shaded areas represent the ranges of normal values. EBV, 
Epstein-Barr virus; HLH, hemophagocytic lymphohistiocytosis; IM, infectious 
mononucleosis; FLH, familial HLH; n.s., not significant. *p < 0.05; ** p < 0.01; *** p ≤ 
0.001. 
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